The Impact of Repeated Nicotine and Alcohol Co-Exposure on the In Vivo Chlorpyrifos Pharmacokinetics and Pharmacodynamics
-
2010/03/01
-
Details
-
Personal Author:
-
Description:Chlorpyrifos (CPF) is an organophosphorus insecticide widely used in agriculture. The neurotoxicity of CPF results from inhibition of cholinesterase (ChE) by its metabolite, chlorpyrifos-oxon (CPF-oxon), which subsequently leads to cholinergic hyperstimulation. The objective of this study was to evaluate the influence of repeated nicotine and ethanol co-exposure on in vivo CPF pharmacokinetics and pharmacodynamics. The routine consumption of tobacco products and alcoholic beverages may modify key metabolic and physiological processes. Blood and urine profiles of the non-toxic metabolite, 3,5,6-trichloro-2-pyridinol (TCPy) along with changes in plasma and brain ChE activities were measured in male S-D rats (approximately 300 g). Animals were co-exposed to CPF (1 or 5 mg/kg/day, po), ethanol (1 g/kg/day, po) and nicotine (1 mg/kg/day, sc), for 7 days. Rats were sacrificed at times from 1 to 24 hr post-last dosing of CPF. There were apparent differences in blood TCPy pharmacokinetics following nicotine and ethanol pretreatment in both CPF dosegroups, which showed higher TCPy peak concentrations and increased blood TCPy AUC (approximately 2-fold) in ethanol/nicotine pretreated groups over saline pretreatment groups. Brain acetylcholinesterase (AChE) activities from ethanol and nicotinetreated groups showed substantially less inhibition following repeated 5 mg CPF/kg dosing compared to CPF-only controls (96 +/- 13 and 66 +/- 7% of naïve at 4 hr postlast dosing, respectively). Inhibition of brain AChE activities was minimal in both 1 mg CPF/kg dosing groups, but a similar trend indicating less inhibition following ethanol/nicotine pretreatment was apparent. No alcohol/nicotine treatment effects were observed in plasma ChE activities. This study shows that repeated exposure to alcohol and nicotine (i.e., from smoking) could alter the pharmacokinetics and pharmacodynamics of CPF. [Description provided by NIOSH]
-
Subjects:
-
Keywords:
-
ISSN:1096-6080
-
Document Type:
-
Funding:
-
Genre:
-
Place as Subject:
-
CIO:
-
Topic:
-
Location:
-
Volume:114
-
Issue:1
-
NIOSHTIC Number:nn:20036664
-
Citation:Toxicologist 2010 Mar; 114(1):340
-
Federal Fiscal Year:2010
-
NORA Priority Area:
-
Performing Organization:Battelle Memorial Institute, Richland, Washington
-
Peer Reviewed:False
-
Start Date:20010930
-
Source Full Name:The Toxicologist. Society of Toxicology 49th Annual Meeting and ToxExpo, March 7-11, 2010, Salt Lake City, Utah
-
End Date:20050929
-
Collection(s):
-
Main Document Checksum:urn:sha-512:c5a01ea88fb6b325b855ae861d1719d31fb203fa59ad0eff6af2b24fd936ffb5ceebf69edfeba1409d7582504f0e15af8ba0a43f636534727ffcd42da0dede29
-
Download URL:
-
File Type:
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like